Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma

Multiple myeloma (MM) survival rates have been substantially increased thanks to novel agents that have improved survival outcomes and shown better tolerability than treatments of earlier years. These new agents include immunomodulating imide drugs (IMiD) thalidomide and lenalidomide, the proteasome...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerchione, Claudio, Nappi, Davide, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464555/
https://www.ncbi.nlm.nih.gov/pubmed/33990881
http://dx.doi.org/10.1007/s00520-021-06266-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464555/
https://www.ncbi.nlm.nih.gov/pubmed/33990881
http://dx.doi.org/10.1007/s00520-021-06266-x

Ejemplares similares